Retrospektive Ergebnisse der perkutanen Strahlentherapie der Tuba Eustachii bei chronischer Otitis media

J. Schultze,C. Reinke,K. A. Frese,B. Kimmig

DOI: https://doi.org/10.1007/s00066-003-1026-z

Abstract:

What problem does this paper attempt to address?

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Ping Ren,Chuyue Zhang,Wenping Li,Xian Wang,Aibing Liang,Guang Yang,Hongtao Xu,Peixiang Ma

DOI: https://doi.org/10.1002/adbi.202101262

2022-01-01

Advanced Biology

Abstract:Chimeric antigen receptors (CAR) redirect T cells to specifically recognize and eliminate tumor cells. CAR-T therapy has achieved successful clinical outcomes, and it has been transformed into commercially available products to treat acute lymphoblastic leukemia and B cell lymphoma. These breakthroughs have motivated hundreds of CAR-T clinical trials initiated each year, with ≈900 cases registered on the ClinicalTrials website till 2021. Accumulating clinical experiences have highlighted some limitations of this strategy, e.g., relapse after complete response, poor efficacy in solid tumors, on-target off-tumor toxicities, lack of persistence, and tumor resistance. These challenges limit the therapeutic application of CAR-T cells. Multidisciplinary approaches are actively investigated to address these issues. In this review, the antigens, CAR designs, and cell sources are summarized in clinical trials from 2020 to 2021. The innovative modular and programmable designs in CAR-T cells, including advances in signaling domains, antigen-recognition domains, T cell engineering, and cell resources, are further discussed. Integrative genetic and chemical engineering strategies are promising to improve the versatility, antitumor efficacy, persistence, and safety of CAR-T cells. In the future, the next generation of CAR-T cell therapies will offer more options for patients who are refractory to standard tumor therapies.
The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

Alberto Boretti

DOI: https://doi.org/10.1016/j.compbiomed.2024.109137

Abstract:This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes.
Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.

M. Uddin,S. Kouzi,M. D. Hussain

DOI: https://doi.org/10.18433/J3RS3V

2015-06-18

Journal of Pharmacy & Pharmaceutical Sciences

Abstract:Human Papillomaviruses (HPV) are a diverse group of small non-enveloped DNA viruses. Some HPVs are classified as low-risk as they are very rarely associated with neoplasia or cancer in the general population, and cause lenient warts. Other HPVs are considered as high-risk types because they are responsible for several important human cancers, including cervical cancer, a large proportion of other anogenital cancers, and a growing number of head and neck cancers. Transmission of HPV occurs primarily by skin-to-skin contact. The risk of contracting genital HPV infection and cervical cancer is influenced by sexual activity. Currently two prophylactic HPV vaccines, Gardasil® (Merck, USA) and Cervarix® (GlaxoSmithKline, UK), are available and recommended for mass immunization of adolescents. However, these vaccines have limitations as they are expensive and require cold chain storage and trained personnel to administer them by injection. The use of nano or micro particulate vaccines could address most of these limitations as they are stable at room temperature, inexpensive to produce and distribute to resource poor regions, and can be administered orally without the need for adjuvants in the formulation. Also it is possible to increase the efficiency of these particulate vaccines by decorating the surface of the nano or micro particulates with suitable ligands for targeted delivery. Oral vaccines, which can be delivered using particulate formulations, have the added potential to stimulate mucosa-associated lymphoid tissue located in the digestive tract and the gut-associated lymphoid tissue, both of which are important for the induction of effective mucosal response against many viruses. In addition, oral vaccines provide the opportunity to reduce production and administration costs and are very patient compliant. This review elaborately discusses different strategies that can be pursued to develop a nano or micro particulate oral vaccine for HPV induced cancers and other diseases.
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alaa Alnefaie,Sarah Albogami,Yousif Asiri,Tanveer Ahmad,Saqer S. Alotaibi,Mohammad M. Al-Sanea,Hisham Althobaiti

DOI: https://doi.org/10.3389/fbioe.2022.797440

IF: 5.7

2022-06-22

Frontiers in Bioengineering and Biotechnology

Abstract:Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the body from pathogenic invaders and can be used as tools to enhance the body's defense mechanisms against cancer by genetically engineering these immune cells. Several strategies have been identified for cancer treatment and evaluated for their efficacy against other diseases such as autoimmune and infectious diseases. One of the most advanced technologies is chimeric antigen receptor (CAR) T-cell therapy, a pioneering therapy in the oncology field. Successful clinical trials have resulted in the approval of six CAR-T cell products by the Food and Drug Administration for the treatment of hematological malignancies. However, there have been various obstacles that limit the use of CAR T-cell therapy as the first line of defense mechanism against cancer. Various innovative CAR-T cell therapeutic designs have been evaluated in preclinical and clinical trial settings and have demonstrated much potential for development. Such trials testing the suitability of CARs against solid tumors and HIV are showing promising results. In addition, new solutions have been proposed to overcome the limitations of this therapy. This review provides an overview of the current knowledge regarding this novel technology, including CAR T-cell structure, different applications, limitations, and proposed solutions.

multidisciplinary sciences
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Alaa Ali,J. Dipersio

DOI: https://doi.org/10.3389/fimmu.2024.1432799

IF: 7.3

2024-09-05

Frontiers in Immunology

Abstract:Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, offering remarkable remission rates in otherwise refractory conditions. However, its expansion into broader oncological applications faces significant hurdles, including limited efficacy in solid tumors, safety concerns related to toxicity, and logistical challenges in manufacturing and scalability. This review critically examines the latest advancements aimed at overcoming these obstacles, highlighting innovations in CAR T-cell engineering, novel antigen targeting strategies, and improvements in delivery and persistence within the tumor microenvironment. We also discuss the development of allogeneic CAR T cells as off-the-shelf therapies, strategies to mitigate adverse effects, and the integration of CAR T cells with other therapeutic modalities. This comprehensive analysis underscores the synergistic potential of these strategies to enhance the safety, efficacy, and accessibility of CAR T-cell therapies, providing a forward-looking perspective on their evolutionary trajectory in cancer treatment.

Medicine,Engineering
Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Lorenzo Giorgioni,Alessandra Ambrosone,Maria Francesca Cometa,Anna Laura Salvati,Robert Nisticò,Armando Magrelli

DOI: https://doi.org/10.3390/ijms251910365

IF: 5.6

2024-09-27

International Journal of Molecular Sciences

Abstract:Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating hematological cancers but faces significant challenges in solid-tumor treatment and overall efficacy. Key limitations include T-cell exhaustion, tumor relapse, immunosuppressive tumor microenvironments (TME), immunogenicity, and antigen heterogeneity. To address these issues, various genetic engineering strategies have been proposed. Approaches such as overexpression of transcription factors or metabolic armoring and dynamic CAR regulation are being explored to improve CAR T-cell function and safety. Other efforts to improve CAR T-cell efficacy in solid tumors include targeting novel antigens or developing alternative strategies to address antigen diversity. Despite the promising preclinical results of these solutions, challenges remain in translating CAR T-cell therapies to the clinic to enable economically viable access to these transformative medicines. The efficiency and scalability of autologous CAR T-cell therapy production are hindered by traditional, manual processes which are costly, time-consuming, and prone to variability and contamination. These high-cost, time-intensive processes have complex quality-control requirements. Recent advancements suggest that smaller, decentralized solutions such as microbioreactors and automated point-of-care systems could improve production efficiency, reduce costs, and shorten manufacturing timelines, especially when coupled with innovative manufacturing methods such as transposons and lipid nanoparticles. Future advancements may include harmonized consumables and AI-enabled technologies, which promise to streamline manufacturing, reduce costs, and enhance production quality.

biochemistry & molecular biology,chemistry, multidisciplinary
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

Xuejia Kang,Nur Mita,Lang Zhou,Siqi Wu,Zongliang Yue,R. Jayachandra Babu,Pengyu Chen

DOI: https://doi.org/10.3390/pharmaceutics16091228

IF: 6.525

2024-09-21

Pharmaceutics

Abstract:Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for hematological cancers, yet it faces significant hurdles, particularly regarding its efficacy in solid tumors and concerning associated adverse effects. This review provides a comprehensive analysis of the advancements and ongoing challenges in CAR-T therapy. We highlight the transformative potential of nanotechnology in enhancing CAR-T therapy by improving targeting precision, modulating the immune-suppressive tumor microenvironment, and overcoming physical barriers. Nanotechnology facilitates efficient CAR gene delivery into T cells, boosting transfection efficiency and potentially reducing therapy costs. Moreover, nanotechnology offers innovative solutions to mitigate cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cutting-edge nanotechnology platforms for real-time monitoring of CAR-T cell activity and cytokine release are also discussed. By integrating these advancements, we aim to provide valuable insights and pave the way for the next generation of CAR-T cell therapies to overcome current limitations and enhance therapeutic outcomes.

pharmacology & pharmacy
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game

Kimberly S. Ku,Jie Tang,Yuan Chen,Yihui Shi

DOI: https://doi.org/10.3390/ijms25105361

IF: 5.6

2024-05-15

International Journal of Molecular Sciences

Abstract:Chimeric antigen receptor (CAR)-T cell immunotherapy represents a cutting-edge advancement in the landscape of cancer treatment. This innovative therapy has shown exceptional promise in targeting and eradicating malignant tumors, specifically leukemias and lymphomas. However, despite its groundbreaking successes, (CAR)-T cell therapy is not without its challenges. These challenges, particularly pronounced in the treatment of solid tumors, include but are not limited to, the selection of appropriate tumor antigens, managing therapy-related toxicity, overcoming T-cell exhaustion, and addressing the substantial financial costs associated with treatment. Nanomedicine, an interdisciplinary field that merges nanotechnology with medical science, offers novel strategies that could potentially address these limitations. Its application in cancer treatment has already led to significant advancements, including improved specificity in drug targeting, advancements in cancer diagnostics, enhanced imaging techniques, and strategies for long-term cancer prevention. The integration of nanomedicine with (CAR)-T cell therapy could revolutionize the treatment landscape by enhancing the delivery of genes in (CAR)-T cell engineering, reducing systemic toxicity, and alleviating the immunosuppressive effects within the tumor microenvironment. This review aims to explore how far (CAR)-T cell immunotherapy has come alone, and how nanomedicine could strengthen it into the future. Additionally, the review will examine strategies to limit the off-target effects and systemic toxicity associated with (CAR)-T cell therapy, potentially enhancing patient tolerance and treatment outcomes.

biochemistry & molecular biology,chemistry, multidisciplinary
Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology

Neil C Chada,John T Wilson

DOI: https://doi.org/10.1016/j.copbio.2024.103179

2024-08-20

Abstract:Despite success in treating hematologic malignancies, chimeric antigen receptor-T cell (CAR-T) therapy still faces multiple challenges that have halted progress, especially against solid tumors. Recent advances in nanoscale engineeirng provide several avenues for overcoming these challenges, including more efficienct programming of CAR-Ts ex vivo, promoting immune responsiveness in the tumor microenvironment (TME) in vivo, and boosting CAR-T function in situ. Here, we summarize recent innovations that leverage nanotechnology to directly address the major obstacles that impede CAR-T therapy from reaching its full potential across various cancer types. We conclude with a commentary on the state of the field and how nanotechnology can shape the future of CAR-T and adoptive cell therapy in immuno-oncology.
Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Yingying Yang,Yongxian Hu,Jiasheng Wang,He Huang

DOI: https://doi.org/10.31547/bct-2018-003

2018-01-01

Abstract:Chimeric antigen receptor(CAR)T cell therapy has demonstrated unprecedented feat in a variety of malignancies, providing a transformative approach to treating patients with hematological malignancies and solid tumors.Although CAR-T cell therapy has shown remarkable anti-tumor activity, toxicities and tumor antigen escape have largely compromised its efficacy.In the case of solid-tumor management, it has shown modest results to date, likely due to heterogeneous antigen expression, an inhibitory tumor microenvironment, and other immunosuppressive factors.The predominant goal for this field now is to achieve more precise tumor recognition and design CARs with more robust proliferative ability.To this end, a multitude of novel CARs and new immunomodulatory antibodies are being developed and tested clinically.Intense efforts are underway to improve the engineering of synthetic immunotherapies and combine these strategies with other agents to amplify immune responses.In this review, we will discuss the current landscape of CAR-T cell therapy, with an emphasis on primary challenges that need to be addressed urgently.In addition, we characterize some newly designed CARs proposed for improving specificity and proliferation of CAR-T cells, offering new insights into improving safety and efficacy of CAR-T cell therapy.
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Antonio Maria Alviano,Marta Biondi,Erica Grassenis,Andrea Biondi,Marta Serafini,Sarah Tettamanti

DOI: https://doi.org/10.3389/fimmu.2024.1407992

2024-06-03

Abstract:Although adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells has achieved unprecedented response rates in patients with certain hematological malignancies, this therapeutic modality is still far from fulfilling its remarkable potential, especially in the context of solid cancers. Antigen escape variants, off-tumor destruction of healthy tissues expressing tumor-associated antigens (TAAs), poor CAR-T cell persistence, and the occurrence of functional exhaustion represent some of the most prominent hurdles that limit CAR-T cell ability to induce long-lasting remissions with a tolerable adverse effect profile. In this review, we summarize the main approaches that have been developed to face such bottlenecks, including the adapter CAR (AdCAR) system, Boolean-logic gating, epitope editing, the modulation of cell-intrinsic signaling pathways, and the incorporation of safety switches to precisely control CAR-T cell activation. We also discuss the most pressing issues pertaining to the selection of co-stimulatory domains, with a focus on strategies aimed at promoting CAR-T cell persistence and optimal antitumor functionality.
Radial Velocities Within the Great Nebula of Orion.

E. B. Frost

DOI: https://doi.org/10.1073/PNAS.1.7.416

1915-07-01

Abstract:The Astrophysical Journal for October, 1914, contained an important paper by MM. Bourget, Fabry, and Buisson of Marseille, summarizing the results of their application to the Orion nebula of the photographic interferometric methods of M. Fabry. They found var'ations 'n the radial velocity from one point to another within the nebula, differences as large as 10 km. per second at points quite close to each other being indicated by local deformations of the interference rings. They also detected graat collective movements, the northeastern region receding, and the southwestern region approaching, relatively to the mean velocity at the trapezium, with velocities of about 5 km. per second. It seemed of interest to repeat these determinations independently by the standard spectrographic method, and toward the close of the winter observations were begun at Yerkes Observatory with the Bruce spectrograph, arranged with a dispersion of one prism. The radial velocity was inferred from the displacements of the hydrogen lines 0 and 7 and the lines of nebulium at X 5007 and 4959. At the position of the western star of the trapezium, No. 619 in Bond's catalogue of stars in the nebula, the radial velocity of the nebula was found from measures .of eight plates (taken occasionally during the past eleven years) to be + 15.6 * 0.5 km. per second (recession). This is the mean of independent measures of each plate by the writer and Mr. C. A. Maney, and it agrees almost exactly with the value of + 15.8 km. found by the observers at Marseille for the region of the trapezium. For several other positions around the trapezium, and not over 2' from it; we obtained values ranging from +6 to +17 km. The probable error for the velocity at one point, from the mean of measures by the two observers of a single plate, should be about == 1.5 km., so that the reality of the difference may be regarded as fully confirmed. Exposures of from two to three hours were required at some of the positions, so that the accumulation of plates was slow, and additional observations will be required when the 'open season' for Orion returns. We must accordingly alter our conceptions of the nebula as an enormous mass of quiescent gas, and regard it as seething with local whirlpools besides perhaps having a considerable motion of rotation as a whole. 416
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Paris Kosti,John Maher,James N. Arnold

DOI: https://doi.org/10.3389/fimmu.2018.01104

IF: 7.3

2018-05-22

Frontiers in Immunology

Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

immunology
CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

R. Tamhane,Siddhesh Warke

Abstract:Cancer is among the leading cause of death around the world. Till now many different types of therapies, medications have been developed for these neoplastic diseases. But due to their restricted effectiveness in accordance with the heterogeneity of cancer cells, there is a constant need for novel therapeutic approaches with improved success, like an immunotherapy that uses and enhances the capacity of the patient’s immune system. Chimeric antigen receptor T cells are T cells that are genetically modified to produce an artificial T cell receptor to target a specific protein. The chimeric antigen receptors are called so as they have both antigen binding and T cell activating functions on a single receptor. CAR T cell therapy uses T cells engineered with CARs for cancer treatment. In this review, we will discuss the basic design of CARs, the different FDA approved CAR T cell therapies in preventing different types of cancer, the factors affecting the therapy and the risks involved around the therapy. Index Terms Chimeric antigen receptors, CAR T cell therapy, Cancer Immunotherapy, tumor, FDA approved therapy.

Medicine
CAR T-cell immunotherapy: The path from the by-road to the freeway?

Lynsey M. Whilding,John Maher

DOI: https://doi.org/10.1016/j.molonc.2015.10.012

2015-10-23

Molecular Oncology

Abstract:Chimeric antigen receptors are genetically encoded artificial fusion molecules that can re-program the specificity of peripheral blood polyclonal T-cells against a selected cell surface target. Unparallelled clinical efficacy has recently been demonstrated using this approach to treat patients with refractory B-cell malignancy. However, the approach is technically challenging and can elicit severe toxicity in patients. Moreover, solid tumours have largely proven refractory to this approach. In this review, we describe the important structural features of CARs and how this may influence function. Emerging clinical experience is summarized in both solid tumours and haematological malignancies. Finally, we consider the particular challenges imposed by solid tumours to the successful development of CAR T-cell immunotherapy, together with a number of innovative strategies that have been developed in an effort to reverse the balance in favour of therapeutic benefit.

oncology
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Amy J Petty,Benjamin Heyman,Yiping Yang,Amy J. Petty

DOI: https://doi.org/10.3390/cancers12040842

2020-03-31

Cancers

Abstract:Chimeric antigen receptors (CAR) are fusion proteins engineered from antigen recognition, signaling, and costimulatory domains that can be used to reprogram T cells to specifically target tumor cells expressing specific antigens. Current CAR-T cell technology utilizes the patient’s own T cells to stably express CARs and has achieved exciting clinical success in the past few years. However, current CAR-T cell therapy still faces several challenges, including suboptimal persistence and potency, impaired trafficking to solid tumors, local immunosuppression within the tumor microenvironment and intrinsic toxicity associated with CAR-T cells. This review focuses on recent strategies to improve the clinical efficacy of CAR-T cell therapy and other exciting CAR approaches currently under investigation, including CAR natural killer (NK) and NKT cell therapies.

oncology
Tuning the performance of CAR T cell immunotherapies

Noah H. Richardson,Jordan B. Luttrell,Jonathan S. Bryant,Damian Chamberlain,Saleem Khawaja,Indira Neeli,Marko Radic

DOI: https://doi.org/10.1186/s12896-019-0576-9

2019-11-29

BMC Biotechnology

Abstract:Abstract Background Simultaneous advances in gene editing, T cell engineering and biotechnology currently provide an opportunity for rapid progress in medicine. The approval of chimeric antigen receptor (CAR) T cell therapies by the US Food and Drug Administration (FDA) and the European Commission have generated substantial momentum for these first-in-class therapies to be used in patients with B cell malignancies. Main body Considerable efforts focus on improved outcomes and reduced side effects of the newly approved therapies. Using innovative strategies, researchers aim to extend CAR T cell use to tackle difficulties inherent in solid tumors. Efforts are underway to broaden the applications of CAR T cells, and the strategy has been successful in chronic viral infections and preclinical models of autoimmunity. Research is in progress to generate “off-the-shelf” CAR T cells, an advance, which would greatly increase patient availability and reduce treatment cost. Conclusions In this thematic review, we highlight advances that may help develop genetically engineered cells into a new category of medical therapies.

biotechnology & applied microbiology
Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Luciano Castiello,Laura Santodonato,Mariarosaria Napolitano,Davide Carlei,Enrica Montefiore,Domenica Maria Monque,Giuseppina D'Agostino,Eleonora Aricò

DOI: https://doi.org/10.3390/cancers14215351

2022-10-30

Abstract:Chimeric antigen receptor T cell therapies are revolutionizing the clinical practice of hematological tumors, whereas minimal progresses have been achieved in the solid tumor arena. Multiple reasons have been ascribed to this slower pace: The higher heterogeneity, the hurdles of defining reliable tumor antigens to target, and the broad repertoire of immune escape strategies developed by solid tumors are considered among the major ones. Currently, several CAR therapies are being investigated in preclinical and early clinical trials against solid tumors differing in the type of construct, the cells that are engineered, and the additional signals included with the CAR constructs to overcome solid tumor barriers. Additionally, novel approaches in development aim at overcoming some of the limitations that emerged with the approved therapies, such as large-scale manufacturing, duration of manufacturing, and logistical issues. In this review, we analyze the advantages and challenges of the different approaches under development, balancing the scientific evidences supporting specific choices with the manufacturing and regulatory issues that are essential for their further clinical development.
'P' Versus 'Q': Differences and Commonalities between the Two Areas of Quantitative Finance

Attilio Meucci

2011-01-22

Abstract:There exist two separate branches of finance that require advanced quantitative techniques: the "Q" area of derivatives pricing, whose task is to "extrapolate the present"; and the "P" area of quantitative risk and portfolio management, whose task is to "model the future."We briefly trace the history of these two branches of quantitative finance, highlighting their different goals and challenges. Then we provide an overview of their areas of intersection: the notion of risk premium; the stochastic processes used, often under different names and assumptions in the Q and in the P world; the numerical methods utilized to simulate those processes; hedging; and statistical arbitrage.
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Caroline Diorio,David T. Teachey,Stephan A. Grupp

DOI: https://doi.org/10.1038/s41571-024-00959-y

IF: 78.8

2024-11-18

Nature Reviews Clinical Oncology

Abstract:Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, conferring durable and sometimes curative responses in patients with advanced-stage disease. The CAR T cell products currently approved for clinical use are all autologous and are often effective; however, in patients who are lymphopenic and/or heavily pretreated with chemotherapy, autologous T cells can be difficult to harvest in sufficient numbers or have functional impairments that might ultimately render them less efficacious. Moreover, autologous products take several weeks to produce, and each product can be used in only one patient. By contrast, allogeneic CAR T cells can be produced for many patients using T cells from a single healthy donor, can be optimized for safety and efficacy, can be instantly available for 'off-the-shelf' use and, therefore, might also be more cost-effective. Despite these potential advantages, the development of allogeneic CAR T cells has lagged behind that of autologous products, owing to the additional challenges such as avoiding graft-versus-host disease and host-mediated graft rejection. Over the past few years, the development of advanced genome-editing techniques has facilitated the generation of novel allogeneic CAR T cell products. Furthermore, CAR cell products derived from other cell types such as induced pluripotent stem cells and natural killer cells are being investigated for clinical use. In this Review, we discuss the potential of allogeneic CAR cell products to expand life-saving immunotherapy to a much broader population of patients in the coming years, the progress made to date and strategies to overcome remaining hurdles.

oncology

Retrospektive Ergebnisse der perkutanen Strahlentherapie der Tuba Eustachii bei chronischer Otitis media

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game

Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Radial Velocities Within the Great Nebula of Orion.

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Tuning the performance of CAR T cell immunotherapies

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

'P' Versus 'Q': Differences and Commonalities between the Two Areas of Quantitative Finance

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks